Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
The Cessation Clinical Trial is looking at how well a digital program can help people quit using tobacco compared to standard methods of care. If you or someone you know uses tobacco products like cigarettes, e-cigarettes, or cigars, this study might be a good fit. The trial is open to adults aged 65 to 74 who currently use tobacco and live in the U.S. Participants will be recruited to see how effective this new digital quit program is in helping them stop using tobacco.
If you join the trial, you can expect to receive support through the digital program, which includes resources and encouragement to help you quit. It's important to note that participants need to have an active text message plan for part of the study. The goal is to find out if this digital approach can make a real difference in helping people stop using tobacco products, which can lead to better health outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Current tobacco use (past 30-day use of one or more of the following: cigarettes, cigars, little cigars, cigarillos, e-cigarettes, or oral nicotine products)
- • US residence
- • Active text message plan (phase 2 only)
- Exclusion Criteria:
- • Age 25 or above (phase 2 only)
About Truth Initiative
Truth Initiative is a leading nonprofit organization dedicated to achieving a culture where all youth and young adults reject smoking, vaping, and nicotine. Through research, advocacy, and innovative public education campaigns, Truth Initiative aims to reduce tobacco use and its associated health risks. The organization sponsors clinical trials and studies that contribute to the understanding of tobacco-related behaviors, inform policy decisions, and promote effective interventions. With a commitment to evidence-based practices and a focus on youth engagement, Truth Initiative plays a pivotal role in advancing public health and fostering a tobacco-free future.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Washington, District Of Columbia, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported